Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Próximos ensaios clínicos
-
University of TennesseeWoodcock Institute for the Advancement of Neurocognitive Research and Applied...Ainda não está recrutandoHabilidades motoras | Saudável | Função executiva
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLCAinda não está recrutandoCarcinoma Anal de Células Escamosas
-
Universita di VeronaAzienda Ospedaliera Universitaria Integrata VeronaAinda não está recrutandoArtrite reumatoide | Doença articular degenerativa do joelhoItália
-
University of Wisconsin, MadisonAlkermes, Inc.Ainda não está recrutando
-
Virginia Commonwealth UniversityAinda não está recrutandoEdema Cerebral | Necrose de RadiaçãoEstados Unidos
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Icahn School of Medicine at Mount...Ainda não está recrutandoCetamina | fMRI | Depressão - Transtorno Depressivo Maior | rTMS | Depressão resistente ao tratamento (TRD)Estados Unidos
-
Weill Medical College of Cornell UniversityBD2 LLCAinda não está recrutandofMRI | Transtorno Bipolar (DB) | rTMS | Depressão Bipolar 1Estados Unidos
-
Xentria, Inc.Ainda não está recrutando
-
Yale UniversityNational Institute of Mental Health (NIMH)Ainda não está recrutando
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeRecrutamentoFeocromocitoma | Feocromocitoma/Paraganglioma | Feocromocitoma Metastático | Feocromocitoma Maligno | Feocromocitoma e paraganglioma (PPGL)Reino Unido
-
Carl Zeiss Meditec-Dublin CoCeRecrutamentoMembrana Epirretiniana | Doença da Retina | Degeneração macular relacionada à idade seca | Anormalidade Vitreorretiniana | Macular Abnormalities | Intraretinal Hyporeflective Space | Subretinal Hyporeflective Space | IS/OS (Ellipsoid Zone) Disruption | Retinal Pigment Epithelium (RPE) Elevation | Retinal...Estados Unidos
-
Celest Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical UniversityRecrutamentoCLDN18.2 Tumores Sólidos PositivosChina
Clinical Research Jobs
-
Czechia - Brno
-
Belgium - Leuven
-
United Kingdom - Tranent
-
Romania - Bucharest
-
United StatesCanada - Québec - Quebec
-
United Kingdom - Guildford
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China
